Suppr超能文献

用于肺动脉心室至肺动脉连接的无支架异种移植管道:这是正确的选择吗?

Stentless heterograft conduits for pulmonic ventricle to pulmonary artery connection: is it the right option?

作者信息

Erek Ersin, Yalcinbas Yusuf Kenan, Salihoglu Ece, Colakoglu Ayse, Sarioglu Ayse, Sarioglu Tayyar

机构信息

Acibadem Heart Center, Acibadem Hospital Bakirkoy, Bakirkoy, Istanbul, Turkey.

出版信息

J Heart Valve Dis. 2006 May;15(3):433-40.

Abstract

BACKGROUND AND AIM OF THE STUDY

A variety of stentless heterograft conduits has been developed as alternatives for pulmonary outflow reconstruction. Herein are reported the authors' results with four different types of stentless heterograft conduit implanted during the past nine years.

METHODS

Between January 1996 and March 2005, stentless heterograft conduits were used in 54 patients (mean age 9.9 +/- 7.5 years; median age 7 years; range: 1-32 years) to reconstruct the pulmonary outflow tract. The main pathologies were tetralogy of Fallot, transposition of the great arteries and aortic valve disease (Ross operation). A Baxter-Edwards Prima valve (EP) was used in three patients, a Medtronic Freestyle bioprosthesis (MF) in 27, a Cryolife Ross pulmonic heterograft (CR) in 14, and a Medtronic Contegra bovine jugular vein conduit (MC) in 10. The mean conduit diameter was 20.4 +/- 1.7 mm (range: 16-23 mm).

RESULTS

Early mortality was 5.5%. Mean intensive care unit and hospital stays were 4.3 +/- 4.8 days and 11.7 +/- 7.2 days, respectively. Clinical follow up was complete for 92.1% of patients; the mean follow up period was 45.6 +/- 20 months. Excluding early deaths, the probability of patient survival (Kaplan-Meier) was 97.9% and 74.6% at one and five years, respectively. Transconduit gradients increased significantly in all conduit types during follow up. Conduit failure occurred in 15 patients (two EP, nine MF, three CR, one MC) at a median duration of 70 +/- 7 months (range: 56-84 months). To date, nine patients have undergone conduit re-replacement, without mortality and major morbidity. The probability of freedom from conduit failure was 91.6%, 66.4% and 27.9% at three, five and seven years, respectively.

CONCLUSION

Stentless heterograft conduits are suitable alternatives to homografts, with acceptable early and mid-term results. However, they do not offer any significant advantage over homografts or other conventional Dacron or pericardial conduits.

摘要

研究背景与目的

已研发出多种无支架异种移植物管道作为肺流出道重建的替代物。本文报告了作者在过去九年中植入四种不同类型无支架异种移植物管道的结果。

方法

1996年1月至2005年3月期间,54例患者(平均年龄9.9±7.5岁;中位年龄7岁;范围:1 - 32岁)使用无支架异种移植物管道重建肺流出道。主要病变包括法洛四联症、大动脉转位和主动脉瓣疾病(Ross手术)。3例患者使用了百特-爱德华兹Prima瓣膜(EP),27例使用了美敦力Freestyle生物假体(MF),14例使用了Cryolife Ross肺动脉异种肺异种肺移植物(CR),10例使用了美敦力Contegra牛颈静脉管道(MC)。管道平均直径为20.4±1.7mm(范围:16 - 23mm)。

结果

早期死亡率为5.5%。重症监护病房平均住院时间和医院平均住院时间分别为4.3±4.8天和11.7±7.2天。92.1%的患者完成了临床随访;平均随访期为45.6±20个月。排除早期死亡病例,患者1年和5年的生存率(Kaplan-Meier法)分别为97.9%和74.6%。随访期间,所有类型管道的跨管道梯度均显著增加。15例患者(2例EP、9例MF、3例CR、1例MC)发生管道故障,中位持续时间为70±7个月(范围:56 - 84个月)。迄今为止,9例患者接受了管道再次置换,无死亡及严重并发症发生。3年、5年和7年无管道故障的概率分别为91.6%、66.4%和27.9%。

结论

无支架异种移植物管道是同种移植物合适的替代物,具有可接受的早期和中期结果。然而,与同种移植物或其他传统的涤纶或心包管道相比,它们没有任何显著优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验